Literature DB >> 16026559

Double-blind, randomized controlled pilot study of bilateral cerebellar stimulation for treatment of intractable motor seizures.

Francisco Velasco1, José D Carrillo-Ruiz, Francisco Brito, Marcos Velasco, Ana Luisa Velasco, Irma Marquez, Ross Davis.   

Abstract

PURPOSE: The efficacy and safety of cerebellar stimulation (CS) was reevaluated in a double-blind, randomized controlled pilot study on five patients with medically refractory motor seizures, and especially generalized tonic-clonic seizures.
METHODS: Bilateral modified four-contact plate electrodes were placed on the cerebellar superomedial surface through two suboccipital burr holes. The implanted programmable, battery-operated stimulator was adjusted to 2.0 microC/cm(2)/phase with the stimulator case as the anode; at this level, no patient experienced the stimulation. Patients served as their own controls, comparing their seizure frequency in preimplant basal phase (BL) of 3 months with the postimplant phases from 10 months to 4 years (average, eight epochs of 3 months each). During the month after implantation, the stimulators were not activated. The patient and the evaluator were blinded as to the next 3-month epoch, as to whether stimulation was used. The patients were randomized into two groups: three with the stimulator ON and two with the stimulator OFF. After a 4-month postimplantation period, all patients had their stimulator ON until the end of the study and beyond. Medication was maintained unchanged throughout the study. EEG paroxysmal discharges also were measured.
RESULTS: Generalized tonic-clonic seizures: in the initial 3-month double-blind phase, two patients were monitored with the stimulation OFF; no change was found in the mean seizure rate (patient 1, 100%, and patient 5, 85%; mean, 93%), whereas the three patients with the stimulation initially ON had a reduction of seizures to 33% (patient 2, 21%; patient 3, 46%; patient 4, 32%) with a statistically significant difference between OFF and ON phase of p = 0.023. All five patients then were stimulated and monitored. At the end of the next 6 months of stimulation, the five patients had a mean seizure rate of 41% (14-75%) of the BL. The second patient developed an infection in the implanted system, which had to be removed after 11 months of stimulation; the seizures were being reduced with stimulation to a mean of one per month from a mean of 4.7 per month (BL level) before stimulation. At the end of 24 months, three patients were monitored with stimulation, resulting in a further reduction of seizures to 24% (11-38%). Tonic seizures: four patients had these seizures, which at 24 months were reduced to 43% (10-76%). Follow-up surgery was necessary in four patients because of infection in one patient and lead/electrode displacement needing repositioning in three patients. The statistical analysis showed a significant reduction in tonic-clonic seizures (p < 0.001) and tonic seizures (p < 0.05).
CONCLUSIONS: The superomedial cerebellar cortex appears to be a significantly effective and safe target for electrical stimulation for decreasing motor seizures over the long term. The effect shows generalized tonic-clonic seizure reduction after 1-2 months and continues to decrease over the first 6 months and then maintains this effectiveness over the study period of 2 years and beyond.

Entities:  

Mesh:

Year:  2005        PMID: 16026559     DOI: 10.1111/j.1528-1167.2005.70504.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  42 in total

Review 1.  Electrical stimulation for epilepsy: experimental approaches.

Authors:  John D Rolston; Sharanya Arcot Desai; Nealen G Laxpati; Robert E Gross
Journal:  Neurosurg Clin N Am       Date:  2011-10       Impact factor: 2.509

2.  Toward a noninvasive automatic seizure control system in rats with transcranial focal stimulations via tripolar concentric ring electrodes.

Authors:  Oleksandr Makeyev; Xiang Liu; Hiram Luna-Munguía; Gabriela Rogel-Salazar; Samuel Mucio-Ramirez; Yuhong Liu; Yan L Sun; Steven M Kay; Walter G Besio
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2012-07       Impact factor: 3.802

Review 3.  Deep brain and cortical stimulation for epilepsy.

Authors:  Mathieu Sprengers; Kristl Vonck; Evelien Carrette; Anthony G Marson; Paul Boon
Journal:  Cochrane Database Syst Rev       Date:  2017-07-18

4.  Outcomes remain ambivalent for deep brain stimulation and epilepsy.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

5.  3-mercaptopropionic acid-induced seizures decrease NR2B expression in Purkinje cells: cyclopentyladenosine effect.

Authors:  E Girardi; J Auzmendi; N Charó; M B Gori; M Castro
Journal:  Cell Mol Neurobiol       Date:  2010-07-13       Impact factor: 5.046

Review 6.  Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials.

Authors:  Nealen G Laxpati; Willard S Kasoff; Robert E Gross
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

7.  Anticonvulsive Activity in Audiogenic DBA/2 Mice of 1,4-Benzodiazepines and 1,5-Benzodiazepines with Different Activities at Cerebellar Granule Cell GABAA Receptors.

Authors:  Elena Gatta; Aroldo Cupello; Mario Di Braccio; Giancarlo Grossi; Mauro Robello; Francesca Scicchitano; Emilio Russo; Giovambattista De Sarro
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

Review 8.  Deep brain stimulation: a new approach to the treatment of epilepsy.

Authors:  Andreas Schulze-Bonhage
Journal:  Dtsch Arztebl Int       Date:  2009-06-12       Impact factor: 5.594

Review 9.  Optogenetic Approaches for Controlling Seizure Activity.

Authors:  Jack K Tung; Ken Berglund; Robert E Gross
Journal:  Brain Stimul       Date:  2016-07-14       Impact factor: 8.955

10.  Deep brain stimulation for epilepsy.

Authors:  Casey H Halpern; Uzma Samadani; Brian Litt; Jurg L Jaggi; Gordon H Baltuch
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.